Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alimemazine pilot study for ADHD with comorbid atopic disease
NL-OMON42065Phase 4Withdrawn
- Sponsor
- Medisch Centrum Leeuwarden
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of alimemazine in attention deficit hyperactivity disorder (ADHD), atopic disease, atopic dermatitis (AD) and 2 more, sponsored by Medisch Centrum Leeuwarden. Planned start Mar 2015; status: withdrawn.
02
Drugs
alimemazine
03
Conditions
attention deficit hyperactivity disorder (ADHD)atopic diseaseatopic dermatitis (AD)asthmaallergic rhinitis (AR)
Beyond the preview
Go deeper on NL-OMON42065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42065.